These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1483641)

  • 1. Implications of the Australian guidelines for the United States.
    Freund DA; Evans D; Henry D; Dittus R
    Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641
    [No Abstract]   [Full Text] [Related]  

  • 2. Basing prescription drug payment on economic analysis: the case of Australia.
    Drummond MF
    Health Aff (Millwood); 1992; 11(4):191-6. PubMed ID: 1483639
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?
    Drummond M
    Health Econ; 1992 Jul; 1(2):85-92. PubMed ID: 1341931
    [No Abstract]   [Full Text] [Related]  

  • 4. Issues in mandatory economic assessment of pharmaceuticals.
    Bloom BS
    Health Aff (Millwood); 1992; 11(4):197-201. PubMed ID: 1483640
    [No Abstract]   [Full Text] [Related]  

  • 5. How well does your PBM perform?
    McCarthy R
    Bus Health; 1999 Jan; 17(1):24-9. PubMed ID: 10345211
    [No Abstract]   [Full Text] [Related]  

  • 6. The need for health care reform.
    Mossinghoff GJ
    Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
    [No Abstract]   [Full Text] [Related]  

  • 7. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
    Viney R
    Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
    [No Abstract]   [Full Text] [Related]  

  • 8. Congress has its brain on drug benefits.
    Birnbaum JH
    Fortune; 2003 Jan; 147(1):178. PubMed ID: 12602124
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 10. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
    Dalton A
    Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474
    [No Abstract]   [Full Text] [Related]  

  • 11. Australia-United States Free Trade Agreement and the Australian Pharmaceutical Benefits Scheme.
    Sainsbury P
    Yale J Health Policy Law Ethics; 2004; 4(2):387-99. PubMed ID: 15536920
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmaceutical situation in the Philippines.
    Hartigan-Go K
    Aust Health Rev; 2001; 24(2):25-31. PubMed ID: 11496467
    [No Abstract]   [Full Text] [Related]  

  • 13. When success sours: PBMs under scrutiny.
    Carroll J
    Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
    [No Abstract]   [Full Text] [Related]  

  • 14. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 15. Health care reform and the pharmaceutical industry.
    Mossinghoff GJ
    Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The subsidy of pharmaceuticals in Australia: processes and challenges.
    Sansom L
    Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 18. PBMs get new role. Seen as key to drug cost control under new benefit.
    Becker C
    Mod Healthc; 2003 Dec 22-29; 33(51):31, 33. PubMed ID: 14723089
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
    Seay M
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
    [No Abstract]   [Full Text] [Related]  

  • 20. Affordable prescription drugs--state and federal action.
    Ohio Nurses Rev; 2003 Aug; 78(7):4. PubMed ID: 15134064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.